Fulgent Genetics Inc (NASDAQ:FLGT) has been given an average broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation.
Brokerages have set a 12-month consensus target price of $5.30 for the company, according to Zacks. Zacks has also assigned Fulgent Genetics an industry rank of 103 out of 256 based on the ratings given to its competitors.
FLGT has been the subject of a number of analyst reports. Zacks Investment Research cut shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Monday, March 18th. Credit Suisse Group cut shares of Fulgent Genetics from an “outperform” rating to a “neutral” rating in a research note on Friday, April 26th.
Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). The company had revenue of $5.37 million for the quarter, compared to analyst estimates of $5.46 million. Fulgent Genetics had a negative return on equity of 7.12% and a negative net margin of 20.33%. On average, sell-side analysts predict that Fulgent Genetics will post -0.16 earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Financial Advisors LLC acquired a new stake in Fulgent Genetics in the fourth quarter valued at approximately $35,000. Brown Advisory Inc. acquired a new stake in Fulgent Genetics in the fourth quarter valued at approximately $46,000. Finally, Old West Investment Management LLC lifted its stake in Fulgent Genetics by 8.5% in the fourth quarter. Old West Investment Management LLC now owns 434,454 shares of the company’s stock valued at $1,377,000 after acquiring an additional 34,140 shares during the last quarter. Hedge funds and other institutional investors own 6.78% of the company’s stock.
About Fulgent Genetics
Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes.
Read More: What is a Lock-Up Period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.